NCT06585488 2026-03-18
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
BeOne Medicines
Phase 1 Recruiting
Clinical Trials
16 trialsNCT06715124 2026-03-02
QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
Quanta Therapeutics
Phase 1 Active not recruiting
NCT07204340 2026-02-27
TLN-372 in Advanced KRAS Mutant Solid Tumors
Treeline Biosciences, Inc.
Phase 1 Recruiting
NCT07030959 2026-02-25
Study of AUBE00 in Patients With Solid Tumors
Chugai Pharmaceutical
Phase 1 Recruiting
NCT05067283 2026-02-12
KANDLELIT-001
Merck Sharp & Dohme LLC
Phase 1 Recruiting
NCT05012618 2025-12-24
A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
Chugai Pharmaceutical
Phase 1 Terminated
NCT06227377 2025-12-24
QTX3034 in Patients With KRAS G12D Mutation
Quanta Therapeutics
Phase 1 Recruiting
NCT05836324 2025-12-18
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Incyte Corporation
Phase 1 Recruiting
NCT06241456 2025-12-09
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Recruiting
NCT06428500 2025-07-25
QTX3046 in Patients With KRAS G12D Mutations
Quanta Therapeutics
Phase 1 Active not recruiting
NCT06332170 2024-07-18
ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors
Hansoh BioMedical R&D Company
Phase 1 Recruiting
NCT03360734 2021-07-12
GATTO
Glycotope GmbH
Phase 1 Completed
NCT02215720 2016-02-10
TORERO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Unknown
NCT00388427 2015-05-28
Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies
University of Pittsburgh
Phase 1 Completed
NCT01702129 2014-09-09
Anti-EGFR Immunoliposomes in Solid Tumors
University Hospital, Basel, Switzerland
Phase 1 Completed
NCT00376727 2010-03-29
Cetuximab in Treating Patients With Advanced Solid Tumors
University of California, Davis
Phase 1 Completed